LIXTE Biotechnology Holdings, Inc. (LIXT)

LIXTE Biotechnology Holdings, Inc. was a small clinical-stage drug developer focused on protein phosphatase inhibitors for cancer. Its lead compound, LB-100, was designed to inhibit the enzyme PP2A and was being tested in combination with chemotherapy and immunotherapy in cancers including small cell lung cancer, ovarian cancer and colorectal cancer, often through investigator-led trials. The company was a small organization that outsourced most of its research and clinical work to academic partners and contract research organizations.

The company's shares moved to the Nasdaq Capital Market in 2020 under the symbol LIXT, after years of trading over the counter. Like many micro-cap biotechs, it relied on equity offerings to fund research and carried a small market value as its trials progressed slowly. Its programs advanced slowly, and the company spent years trying to secure partners for later-stage development of LB-100.

In 2026 LIXTE completed a merger with NOMAD Transportable Power Systems, a company that sells, rents and provides energy as a service using battery energy storage systems mounted on semi-trailers. The combined company targets AI and hyperscale data centers, utilities and other customers that need mobile power, and said it plans to exit the legacy cancer drug business through a sale or other transaction.

To reflect the new strategy, the company changed its name to NOMAD Power Solutions, Inc. The LIXT ticker ceased trading at the close of the market on July 2, 2026, and the stock began trading on Nasdaq under NMAD on July 6, 2026. The change gave existing shareholders a stake in the combined power equipment business, while the former biotech programs were set aside for sale.